Investors
Helix BioMedix, Inc, is committed to building long term shareholder value through strategic management of our diverse peptide library.
The company’s stock symbol is HXBM.OB. For a complete listing of reports and filings please visit the Securities and Exchange Commission at www.sec.gov…click to learn more
Management Team…click to learn more.
Board of Directors…click to learn more.
The Management and Board of Directors of Helix BioMedix Inc. are committed to operating the company in an efficient, compliant and ethical manner, thereby improving our ability for growth and creation of value for our stockholders…click to learn more.
Helix BioMedix, Inc. is pleased to offer the following online services…click to learn more.

Online Access to Annual Report and Proxy Statement
Electronic Proxy Voting
Beneficial Stockholders
Registered Stockolders

NEW REPORTS
Stockholder Update May 2018 [PDF]
Stockholder Update Febuary 2018 [PDF]
Stockholder Update November 2017 [PDF]
Stockholder Update September 2017 [PDF]
CEO Letter June 2017 [PDF]
CEO Letter February 2017 [PDF]
CEO Letter December 2016 [PDF]
CEO Letter August 2016 [PDF]
Stockholders Letter July 2016 [PDF]
CEO Letter June 2016 [PDF]
CEO Letter February 2016 [PDF]
CEO Letter December 2015 [PDF]
CEO Letter September 2015 [PDF]
CEO Letter June 2015 [PDF]
CEO Letter February 2015 [PDF]
CEO Letter November 2014 [PDF]
CEO Letter August 2014 [PDF]

TRANSFER AGENT
Website: www.shareholder.broadridge.com
E-mail: shareholder@broadridge.com
Telephone:  1-877-830-4936 or 720-378-5591

Mail:
Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, NY   11717   USA

INVESTOR RELATIONS CONTACT
R. Stephen Beatty
425.402.8400
sbeatty@helixbiomedix.com

STOCK SPLIT FAQs
Cover Letter
Frequently Asked Questions for the AST Transmittal Letter